Latest Europe News

Integrated Research’s FY26 results reveal a sharp 91% drop in net profit amid softer renewals and rising expenses, offset by a 27% jump in cash and a special dividend. The company pushes forward with AI-powered products despite early-stage commercialisation risks.

Ainsworth Game Technology’s first half 2026 results reveal a sharp revenue drop driven by North American and Latin American market pressures, offset partially by Asia Pacific growth and a key patent licensing deal.

Genetic Signatures (ASX: GSS) and Microba Life Sciences (ASX: MAP) are in early talks about merging to form a larger infectious disease diagnostics entity, combining rapid pathogen detection with microbiome profiling. The proposed group would have FY2026 pro forma revenue of around A$29 million and a stronger financial footing.

Neuren Pharmaceuticals reported an 8% rise in H1 2026 revenues driven by DAYBUE royalties, but profit fell 68% due to ramped-up R&D. The company declared its first ever dividend, signalling confidence amid ongoing clinical and regulatory milestones.

Domino’s Pizza Enterprises reported a $134.2 million statutory loss for FY26 due to significant non-cash impairments, while underlying profit rose 4%. The company is closing up to 60 stores and focusing on franchisee profitability and cost reductions.

DroneShield Limited reported record revenue of $125.8 million for the half-year ended June 2026, driven by recurring income and geographic diversification, while posting a $32.2 million statutory loss due to margin pressure and strategic investments.

L1 Global Long Short Fund (ASX:GLS) reported a striking $121.3 million net profit for FY26 following its strategic reset, declaring a fully franked 2.00 cent final dividend and targeting 8.00 cents per share for FY27.

Lovisa Holdings reported a robust FY26 with revenue up 17.6% to A$938.8 million, expanded its global store network to 1,136 locations, and declared a 33 cent final dividend, reflecting strong momentum in key markets.

Scott Technology aims to more than double Protein Domain revenue to NZ$165 million by FY30, leveraging global growth of its BladeStop safety bandsaw and a new Mexico distribution deal.

Scales Corporation delivered a record first half in 2026 with revenues soaring 105% to NZ$762.1 million and underlying EBITDA up 18% to NZ$102.2 million. The diversified agribusiness raised its full year profit guidance despite challenges in Europe and the Middle East.

Neurizon Therapeutics has completed enrolment in its pivotal HEALEY ALS Platform Trial ahead of schedule, secured critical manufacturing and funding agreements, and reduced its net loss for FY2026 while preparing for topline results in late Q2 2027.

HighCom Limited’s FY26 results reveal a sharp revenue drop and widening loss driven by a US Government shutdown, but a strengthened leadership team and expanded global sales pipeline set the stage for recovery.